Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the antipyretic effect of bromocriptine in critically-ill patients with acute neurologic injury and fever from infectious and non-infectious etiologies.

Clinical Trial Description

In patients with acute neurologic injury such as subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH), traumatic brain injury (TBI), subdural hematoma (SDH), and ischemic stroke, fever has been found to be an independent predictor of poor outcome including increased mortality rates, longer hospital stays, depressed level of consciousness, and worse functional outcomes. Our current antipyretic therapy of acetaminophen and sometimes nonsteroidal anti-inflammatory drugs are not very effective and external cooling requires sedatives and other medications to prevent shivering and pain. Bromocriptine is a dopamine D2 receptor agonist which acts at the hypothalamus, a specific area of the brain that regulates body temperature. Fevers of both central and infectious etiologies must be regulated through the hypothalamus and we have evidence that bromocriptine has an antipyretic effect at the hypothalamus; thus, we hypothesize that bromocriptine could be used safely and more broadly to treat all fevers in the acute setting and not just refractory central fevers in this patient population.

Here, we propose to evaluate the acute antipyretic effects of bromocriptine in this critically-ill population through a pilot, open label, blinded endpoint, randomized controlled trial. In both enrolling centers, University of California, San Francisco Medical Center Parnassus (UCSF) and Zuckerberg San Francisco General Hospital, every patient who is admitted to the neurointensive care unit for an anticipated stay of greater than 48 hours with a diagnosis of subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH), traumatic brain injury (TBI), subdural hematoma (SDH), and ischemic stroke will be screened and consented. If they have a temperature reading ≥ 38.3 ºC, the investigational pharmacy will randomize them to the control arm of acetaminophen or the intervention arm of acetaminophen and bromocriptine for 48 hours. We will continuously measure their temperature and other vitals data. Retrospectively, we will review imaging and labs ordered to work up infectious etiologies of fever. The ICU nurse will do a 5 minute assessment at hour 12, 24, 36 and 48 for side effects if the patient is capable of answering. The temperature data will be analyzed between the two study arms. ;

Study Design

Related Conditions & MeSH terms

NCT number NCT03496545
Study type Interventional
Source University of California, San Francisco
Contact Judy H Ch'ang, MD
Phone 415-502-1453
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date July 1, 2018
Completion date March 2, 2019

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03648476 - Intervention to Change Attributions That Are Negative (ICAN) N/A
Recruiting NCT02059941 - Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP) Monitoring Guidelines N/A
Recruiting NCT03307070 - Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury N/A
Not yet recruiting NCT03559114 - PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST) Phase 3
Not yet recruiting NCT03227354 - Validation of Non-invasive Absolute Intracranial Pressure Monitoring N/A
Not yet recruiting NCT03035838 - Importance of Substance P in Intracranial Pressure Elevation Following Traumatic Brain Injury Early Phase 1
Recruiting NCT02962349 - TRansfusion Strategies in Acute Brain INjured Patients N/A
Active, not recruiting NCT02339220 - The Brave Initiative: Bringing Rehabilitation to American Veterans in an Enriched Environment N/A
Not yet recruiting NCT02698449 - Neurorehabilitation After Traumatic Brain Injury: Functional Magnetic Resonance Imaging Study N/A
Completed NCT02836951 - Rapid Diagnostics for Traumatic Brain Injury (TBI) N/A
Recruiting NCT02613936 - Transcranial Direct Current Stimulation for the Treatment of Deficits After Traumatic Brain Injury N/A
Recruiting NCT03373331 - Treating Emotional Processing Impairments in Individuals With TBI N/A
Recruiting NCT02255799 - Multicenter Evaluation of Memory Remediation After TBI With Donepezil Phase 3
Recruiting NCT02465242 - Pupillometry for the Prediction of Neurologic Outcomes in Severe Traumatic Brain Injury N/A
Active, not recruiting NCT02424656 - Alterations in the Brain's Connectome After Severe Traumatic Brain Injury
Terminated NCT02218216 - TBI MR Study 3 Houston Methodist N/A
Withdrawn NCT02148367 - Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Subacute TBI Phase 2
Not yet recruiting NCT02148783 - Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI Phase 2
Active, not recruiting NCT01874847 - PLAY GAME: Post-concussion Syndrome in Youth - Assessing the GABAergic Effects of Melatonin Phase 2/Phase 3
Active, not recruiting NCT01606111 - The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery Phase 4